These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 25504371)
1. Elevated Slit2 Activity Impairs VEGF-Induced Angiogenesis and Tumor Neovascularization in EphA2-Deficient Endothelium. Youngblood V; Wang S; Song W; Walter D; Hwang Y; Chen J; Brantley-Sieders DM Mol Cancer Res; 2015 Mar; 13(3):524-37. PubMed ID: 25504371 [TBL] [Abstract][Full Text] [Related]
2. Angiocrine factors modulate tumor proliferation and motility through EphA2 repression of Slit2 tumor suppressor function in endothelium. Brantley-Sieders DM; Dunaway CM; Rao M; Short S; Hwang Y; Gao Y; Li D; Jiang A; Shyr Y; Wu JY; Chen J Cancer Res; 2011 Feb; 71(3):976-87. PubMed ID: 21148069 [TBL] [Abstract][Full Text] [Related]
3. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364 [TBL] [Abstract][Full Text] [Related]
4. Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Brantley-Sieders DM; Fang WB; Hwang Y; Hicks D; Chen J Cancer Res; 2006 Nov; 66(21):10315-24. PubMed ID: 17079451 [TBL] [Abstract][Full Text] [Related]
5. Slit2 suppresses endothelial cell proliferation and migration by inhibiting the VEGF-Notch signaling pathway. Li GJ; Yang Y; Yang GK; Wan J; Cui DL; Ma ZH; Du LJ; Zhang GM Mol Med Rep; 2017 Apr; 15(4):1981-1988. PubMed ID: 28260032 [TBL] [Abstract][Full Text] [Related]
6. Cooperative signaling between Slit2 and Ephrin-A1 regulates a balance between angiogenesis and angiostasis. Dunaway CM; Hwang Y; Lindsley CW; Cook RS; Wu JY; Boothby M; Chen J; Brantley-Sieders DM Mol Cell Biol; 2011 Feb; 31(3):404-16. PubMed ID: 21135133 [TBL] [Abstract][Full Text] [Related]
12. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Brantley DM; Cheng N; Thompson EJ; Lin Q; Brekken RA; Thorpe PE; Muraoka RS; Cerretti DP; Pozzi A; Jackson D; Lin C; Chen J Oncogene; 2002 Oct; 21(46):7011-26. PubMed ID: 12370823 [TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Dobrzanski P; Hunter K; Jones-Bolin S; Chang H; Robinson C; Pritchard S; Zhao H; Ruggeri B Cancer Res; 2004 Feb; 64(3):910-9. PubMed ID: 14871820 [TBL] [Abstract][Full Text] [Related]
14. Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway. Zhang J; Ye J; Ma D; Liu N; Wu H; Yu S; Sun X; Tse W; Ji C Carcinogenesis; 2013 Mar; 34(3):667-77. PubMed ID: 23239744 [TBL] [Abstract][Full Text] [Related]
15. Slit2 Promotes Angiogenic Activity Via the Robo1-VEGFR2-ERK1/2 Pathway in Both In Vivo and In Vitro Studies. Li S; Huang L; Sun Y; Bai Y; Yang F; Yu W; Li F; Zhang Q; Wang B; Geng JG; Li X Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5210-7. PubMed ID: 26244297 [TBL] [Abstract][Full Text] [Related]
16. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF. Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784 [TBL] [Abstract][Full Text] [Related]
17. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. Zhao Y; Adjei AA Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391 [TBL] [Abstract][Full Text] [Related]
18. Targeting Slit-Roundabout signaling inhibits tumor angiogenesis in chemical-induced squamous cell carcinogenesis. Wang LJ; Zhao Y; Han B; Ma YG; Zhang J; Yang DM; Mao JW; Tang FT; Li WD; Yang Y; Wang R; Geng JG Cancer Sci; 2008 Mar; 99(3):510-7. PubMed ID: 18201275 [TBL] [Abstract][Full Text] [Related]